{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T19:16:17Z","timestamp":1794597377023,"version":"4.9.1"},"reference-count":106,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Hoffmann-La Roche Canada","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2024,12,18]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Dual inhibition of the angiopoietin (Ang)\/Tie and vascular endothelial growth factor (VEGF) signalling pathways in patients with retinal diseases, such as neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME), may induce greater vascular stability and contribute to increased treatment efficacy and durability compared with treatments that only target the VEGF pathway. Faricimab, a bispecific intravitreal agent that inhibits both VEGF and Ang-2, is the first injectable ophthalmic drug to achieve treatment intervals of up to 16 weeks in Phase 3 studies for nAMD and DME while exhibiting improvements in visual acuity and retinal thickness. Data from real-world studies have supported the safety, visual and anatomic benefits and durability of faricimab, even in patients who were previously treated with other intravitreal agents. These evidence-based expert recommendations from a panel of retina specialists consolidate current evidence with clinical experience for the optimal use of faricimab in patients with nAMD or DME, with a focus on switching from an anti-VEGF agent to faricimab.<\/jats:p>","DOI":"10.1136\/bmjophth-2024-001967","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T02:40:12Z","timestamp":1737081612000},"page":"e001967","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations"],"prefix":"10.1136","volume":"10","author":[{"given":"David T","family":"Wong","sequence":"first","affiliation":[{"name":"Ophthalmology & Vision Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheer","family":"Aboobaker","sequence":"additional","affiliation":[{"name":"Toronto Retina Institute, North York, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Maberley","sequence":"additional","affiliation":[{"name":"Ophthalmology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Sharma","sequence":"additional","affiliation":[{"name":"Ophthalmology and Epidemiology, Queen's University School of Medicine, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeepa","family":"Yoganathan","sequence":"additional","affiliation":[{"name":"Ophthalmology & Vision Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"2026010721201362000_10.1.e001967.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.009"},{"key":"2026010721201362000_10.1.e001967.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.011"},{"key":"2026010721201362000_10.1.e001967.3","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1007\/s12325-022-02326-8","article-title":"Outcomes of Over 40,000 Eyes Treated for Diabetic Macula Edema in Routine Clinical Practice: A Systematic Review and Meta-analysis","volume":"39","author":"Mehta","year":"2022","journal-title":"Adv Ther"},{"key":"2026010721201362000_10.1.e001967.4","first-page":"1731","article-title":"Targeting the Angiopoietin\/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders","volume":"81","author":"Akwii","year":"2021","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026010721201362000_10.1.e001967.5","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"},{"key":"2026010721201362000_10.1.e001967.6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070459","article-title":"Angiopoietin-2 is critical for cytokine-induced vascular leakage","volume":"8","author":"Benest","year":"2013","journal-title":"PLoS ONE"},{"key":"2026010721201362000_10.1.e001967.7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00417-013-2562-6","article-title":"Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research","volume":"252","author":"Wolf","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jfo.2014.11.015","article-title":"Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting","volume":"38","author":"Boulanger-Scemama","year":"2015","journal-title":"J Fr Ophtalmol"},{"key":"2026010721201362000_10.1.e001967.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.12.002"},{"key":"2026010721201362000_10.1.e001967.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.05.017"},{"key":"2026010721201362000_10.1.e001967.11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3341\/kjo.2016.0125","article-title":"Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience","volume":"31","author":"Ozkaya","year":"2017","journal-title":"Korean J Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.12","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305327"},{"key":"2026010721201362000_10.1.e001967.13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/11206721211001716","article-title":"Burden of disease assessment in patients with neovascular age-related macular degeneration in Spain: Results of the AMD-MANAGE study","volume":"32","author":"Pina Mar\u00edn","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.oret.2020.09.024","article-title":"Patient-Reported Complications after Intravitreal Injection and Their Predictive Factors","volume":"5","author":"Ramos","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"2026010721201362000_10.1.e001967.15","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S185052"},{"key":"2026010721201362000_10.1.e001967.16","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2147\/OPTH.S100168","article-title":"Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion","volume":"10","author":"Sivaprasad","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2217\/cer-2018-0058","article-title":"The economic and humanistic burden of patients in receipt of current available therapies for neovascular age-related macular degeneration","volume":"7","author":"Jaffe","year":"2018","journal-title":"J Comp Eff Res"},{"key":"2026010721201362000_10.1.e001967.18","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s00417-019-04456-2","article-title":"Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept","volume":"257","author":"Hara","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.19","first-page":"779","article-title":"Non-responsiveness and tachyphylaxis to anti-vascular endothelial growth factor treatment in naive patients with exudative age-related macular degeneration","volume":"70","author":"Zuber-Laskawiec","year":"2019","journal-title":"J Physiol Pharmacol"},{"key":"2026010721201362000_10.1.e001967.20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3928\/23258160-20180221-03","article-title":"Switching Anti-Vascular Endothelial Growth Factors in Refractory Neovascular Age-Related Macular Degeneration","volume":"49","author":"Ashraf","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2026010721201362000_10.1.e001967.21","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s00417-020-05059-y","article-title":"Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting","volume":"259","author":"Granstam","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.22","doi-asserted-by":"crossref","first-page":"6835782","DOI":"10.1155\/2017\/6835782","article-title":"Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results","volume":"2017","author":"Neves Cardoso","year":"2017","journal-title":"J Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.23","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00417-020-04730-8","article-title":"Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration","volume":"258","author":"Marquis","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.24","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3928\/23258160-20170829-10","article-title":"Switching Anti-VEGF Drugs in the Treatment of Diabetic Macular Edema","volume":"48","author":"Banaee","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2026010721201362000_10.1.e001967.25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2147\/OPTH.S158268","article-title":"Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab","volume":"12","author":"Nixon","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.26","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s12325-019-00971-0","article-title":"How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview","volume":"36","author":"Empeslidis","year":"2019","journal-title":"Adv Ther"},{"key":"2026010721201362000_10.1.e001967.27","unstructured":"Genentech, Inc . Vabysmo (faricimab-svoa) Prescribing Information; 2024."},{"key":"2026010721201362000_10.1.e001967.28","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505889"},{"key":"2026010721201362000_10.1.e001967.29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"The Lancet"},{"key":"2026010721201362000_10.1.e001967.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6"},{"key":"2026010721201362000_10.1.e001967.31","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1967714","article-title":"Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins","volume":"13","author":"Surowka","year":"2021","journal-title":"MAbs"},{"key":"2026010721201362000_10.1.e001967.32","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","article-title":"Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial","volume":"138","author":"Sahni","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.33","first-page":"2522","article-title":"Angiopoietin-2 (Ang-2) signaling and vascular stability with faricimab in diabetic macular edema (DME)","volume":"63","author":"Modi","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026010721201362000_10.1.e001967.34","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.65.10.15"},{"key":"2026010721201362000_10.1.e001967.35","doi-asserted-by":"crossref","first-page":"21128","DOI":"10.1038\/s41598-023-48190-6","article-title":"Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration","volume":"13","author":"Tamiya","year":"2023","journal-title":"Sci Rep"},{"key":"2026010721201362000_10.1.e001967.36","first-page":"2633","article-title":"Faricimab causes rapid and sustained intraocular suppression of Ang-2 and VEGF-A for up to 16 weeks in nAMD and DME","volume":"64","author":"Bogman","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026010721201362000_10.1.e001967.37","doi-asserted-by":"crossref","first-page":"114342","DOI":"10.1016\/j.addr.2022.114342","article-title":"Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies","volume":"187","author":"Alshaikh","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"2026010721201362000_10.1.e001967.38","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0408-4"},{"key":"2026010721201362000_10.1.e001967.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014"},{"key":"2026010721201362000_10.1.e001967.40","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR: A Randomized Controlled Trial","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"},{"key":"2026010721201362000_10.1.e001967.41","doi-asserted-by":"crossref","first-page":"100111","DOI":"10.1016\/j.xops.2021.100111","article-title":"YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale","volume":"2","author":"Eter","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"2026010721201362000_10.1.e001967.42","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41433-021-01831-4","article-title":"Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials","volume":"36","author":"Sharma","year":"2022","journal-title":"Eye (Lond)"},{"key":"2026010721201362000_10.1.e001967.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.12.026"},{"key":"2026010721201362000_10.1.e001967.44","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye (Lond)"},{"key":"2026010721201362000_10.1.e001967.45","unstructured":"Borkar D , Tabano D , Garmo V , et al . FARETINA-amd \u2013 early treatment patterns and outcomes in patients with neovascular age-related macular degeneration initiating faricimab: an iris registry analysis. Presented at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology; New Orleans (Louisiana), 2023"},{"key":"2026010721201362000_10.1.e001967.46","unstructured":"Patel PJ , Talks J , Salvo G , et al . Real-world use of faricimab to treat namd patients in the uk (farwide study). Presented at the 2023 American Society of Retinal Specialists Annual Meeting; Seattle (Washington), 2023"},{"key":"2026010721201362000_10.1.e001967.47","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S409822"},{"key":"2026010721201362000_10.1.e001967.48","article-title":"Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration","volume":"15","author":"Cheng","year":"2023","journal-title":"Cureus"},{"key":"2026010721201362000_10.1.e001967.49","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00417-023-06319-3","article-title":"Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study","volume":"262","author":"Grimaldi","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.50","doi-asserted-by":"crossref","first-page":"8747","DOI":"10.1038\/s41598-023-35759-4","article-title":"Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan","volume":"13","author":"Mukai","year":"2023","journal-title":"Sci Rep"},{"key":"2026010721201362000_10.1.e001967.51","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1007\/s00417-023-06116-y","article-title":"Short-term outcomes of intravitreal faricimab for treatment-na\u00efve neovascular age-related macular degeneration","volume":"261","author":"Matsumoto","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.52","unstructured":"Nielsen J , Kahn H , Aziz A , et al . Real world efficacy, durability and safety of faricimab in diabetic macular edema: the tahoe study. Presented at the 2023 EURETINA Annual Meeting; Amsterdam (Netherlands), 2023"},{"key":"2026010721201362000_10.1.e001967.53","unstructured":"Borkar D , Tabano D , Garmo V , et al . Early treatment patterns and outcomes in patients with diabetic macular edema treated with faricimab: the faretina-dme study. Presented at the 2023 Annual Meeting of the American Society of Retinal Specialists; 2023"},{"key":"2026010721201362000_10.1.e001967.54","unstructured":"Bailey C , Peto T , Downey L , et al . FARWIDE-dme: early treatment patterns of faricimab among dme patients in the uk. Presented at the 2023 EURETINA Annual Meeting; Amsterdam (Netherlands), 2023"},{"key":"2026010721201362000_10.1.e001967.55","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59040665"},{"key":"2026010721201362000_10.1.e001967.56","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","article-title":"Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic","volume":"37","author":"Stanga","year":"2023","journal-title":"Eye (Lond)"},{"key":"2026010721201362000_10.1.e001967.57","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.2147\/OPTH.S381503","article-title":"Faricimab for Treatment-Resistant Diabetic Macular Edema","volume":"16","author":"Rush","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.58","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S424315"},{"key":"2026010721201362000_10.1.e001967.59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","article-title":"Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy","volume":"8","author":"Szigiato","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"2026010721201362000_10.1.e001967.60","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","article-title":"Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration","volume":"8","author":"Pandit","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"2026010721201362000_10.1.e001967.61","doi-asserted-by":"crossref","first-page":"1346322","DOI":"10.3389\/fopht.2023.1346322","article-title":"Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population","volume":"3","author":"Ibrahim","year":"2023","journal-title":"Front Ophthalmol (Lausanne)"},{"key":"2026010721201362000_10.1.e001967.62","article-title":"Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration","volume":"14","author":"Ng","year":"2024","journal-title":"Life (Basel)"},{"key":"2026010721201362000_10.1.e001967.63","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06222-x"},{"key":"2026010721201362000_10.1.e001967.64","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s10384-023-01024-4","article-title":"Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration","volume":"67","author":"Hikichi","year":"2023","journal-title":"Jpn J Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.65","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.3390\/jcm12155145","article-title":"Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration","volume":"12","author":"Kishi","year":"2023","journal-title":"J Clin Med"},{"key":"2026010721201362000_10.1.e001967.66","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S424314"},{"key":"2026010721201362000_10.1.e001967.67","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59061125"},{"key":"2026010721201362000_10.1.e001967.68","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s41669-023-00465-4","article-title":"Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis","volume":"8","author":"B\u00fchrer","year":"2024","journal-title":"Pharmacoecon Open"},{"key":"2026010721201362000_10.1.e001967.69","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s40123-024-00999-8","article-title":"Economic Assessment in Resource-Constrained Systems: Individual-Level Simulation Model in Wet Age-Related Macular Degeneration and Diabetic Macular Oedema","volume":"13","author":"Li","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"2026010721201362000_10.1.e001967.70","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41433-024-03043-y","article-title":"An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective","volume":"38","author":"Meunier","year":"2024","journal-title":"Eye (Lond)"},{"key":"2026010721201362000_10.1.e001967.71","doi-asserted-by":"crossref","unstructured":"Abdalla S , Westborg I , Pulkki\u2010Br\u00e4nnstr\u00f6m A , et al . Faricimab versus bevacizumab for neovascular age\u2010related macular degeneration: Cost analysis based on real\u2010world data from the Swedish Macula Registry. Acta Ophthalmol (Copenh) 2024. doi:10.1111\/aos.16774","DOI":"10.1111\/aos.16774"},{"key":"2026010721201362000_10.1.e001967.72","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1038\/s41433-024-03223-w","article-title":"Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists","volume":"38","author":"Downey","year":"2024","journal-title":"Eye (Lond)"},{"key":"2026010721201362000_10.1.e001967.73","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye (Lond)"},{"key":"2026010721201362000_10.1.e001967.74","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1038\/s41433-024-03110-4","article-title":"Impact of treat and extend criteria on proportions that can be extended after loading phase of 2\u2009mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5","volume":"38","author":"Thottarath","year":"2024","journal-title":"Eye (Lond)"},{"key":"2026010721201362000_10.1.e001967.75","first-page":"92","article-title":"Faricimab in the Treatment Landscape for Retinal Diseases: A Review","volume":"16","author":"Wu","year":"2022","journal-title":"US Ophthalmic Rev"},{"key":"2026010721201362000_10.1.e001967.76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/vision3030041","article-title":"Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients","volume":"3","author":"Skelly","year":"2019","journal-title":"Vision (Basel)"},{"key":"2026010721201362000_10.1.e001967.77","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1111\/aos.13031","article-title":"Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study","volume":"95","author":"Hatz","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.78","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-310822"},{"key":"2026010721201362000_10.1.e001967.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.07.014"},{"key":"2026010721201362000_10.1.e001967.80","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","article-title":"Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study","volume":"126","author":"Kertes","year":"2019","journal-title":"Ophthalmology"},{"key":"2026010721201362000_10.1.e001967.81","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/OPTH.S174560","article-title":"Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group","volume":"12","author":"Amoaku","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.82","first-page":"296","article-title":"Recommended Guidelines for Use of Intravitreal Aflibercept With a Treat-and-Extend Regimen for the Management of Neovascular Age-Related Macular Degeneration in the Asia-Pacific Region: Report From a Consensus Panel","volume":"6","author":"Koh","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"2026010721201362000_10.1.e001967.83","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41433-019-0670-1","article-title":"Faricimab: expanding horizon beyond VEGF","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"},{"key":"2026010721201362000_10.1.e001967.84","unstructured":"Clinicaltrials.gov . NCT05569148: a study in patients with neovascular age-related macular degeneration or diabetic macular edema to evaluate the safety of the faricimab prefilled syringe. Available: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05569148 [Accessed 20 Sep 2024]."},{"key":"2026010721201362000_10.1.e001967.85","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2147\/OPTH.S393519","article-title":"Reported Rates of Intraocular Inflammation with Intravitreal Aflibercept Administered via Pre-Filled Syringe or from Vials in Clinical Practice Between 2012 and 2022","volume":"17","author":"Schmidt-Ott","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.86","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40942-022-00375-3","article-title":"Accuracy of intravitreal injection volume for aflibercept pre-filled syringe and BD Luer-Lok one-milliliter syringe","volume":"8","author":"Guest","year":"2022","journal-title":"Int J Retina Vitreous"},{"key":"2026010721201362000_10.1.e001967.87","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1208\/s12249-021-01949-4","article-title":"Container Closure and Delivery Considerations for Intravitreal Drug Administration","volume":"22","author":"Parenky","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"2026010721201362000_10.1.e001967.88","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ajo.2018.11.023","article-title":"The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab","volume":"199","author":"Storey","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.89","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/24741264231191339","article-title":"Impact of Prefilled Syringes and Masking on Postintravitreal Injection Endophthalmitis","volume":"7","author":"Louis","year":"2023","journal-title":"J Vitreoretin Dis"},{"key":"2026010721201362000_10.1.e001967.90","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.06.059"},{"key":"2026010721201362000_10.1.e001967.91","doi-asserted-by":"crossref","first-page":"e869","DOI":"10.1111\/aos.14691","article-title":"Systemic counterregulatory response of angiopoietin-2 after aflibercept therapy for nAMD: a potential escape mechanism","volume":"99","author":"Angermann","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"2026010721201362000_10.1.e001967.92","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70269-7"},{"key":"2026010721201362000_10.1.e001967.93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.11.029"},{"key":"2026010721201362000_10.1.e001967.94","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307595"},{"key":"2026010721201362000_10.1.e001967.95","doi-asserted-by":"crossref","first-page":"39301","DOI":"10.1038\/srep39301","article-title":"Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-Analysis","volume":"6","author":"Zhou","year":"2016","journal-title":"Sci Rep"},{"key":"2026010721201362000_10.1.e001967.96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000514991","article-title":"Retinal Pigment Epithelium Tears after Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration","volume":"245","author":"Ahn","year":"2022","journal-title":"Ophthalmologica"},{"key":"2026010721201362000_10.1.e001967.97","unstructured":"Regeneron Pharmaceuticals Inc . EYLEA (aflibercept) injection prescribing information. 2011."},{"key":"2026010721201362000_10.1.e001967.98","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.ophtha.2011.05.026","article-title":"Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration","volume":"118","author":"Cunningham","year":"2011","journal-title":"Ophthalmology"},{"key":"2026010721201362000_10.1.e001967.99","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1097\/IAE.0000000000002016","article-title":"IMAGING OF PIGMENT EPITHELIAL DETACHMENTS WITH OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY","volume":"38","author":"Tan","year":"2018","journal-title":"Retina (Philadelphia, Pa)"},{"key":"2026010721201362000_10.1.e001967.100","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.05.008"},{"key":"2026010721201362000_10.1.e001967.101","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/PPA.S347713","article-title":"Drivers of and Barriers to Adherence to Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Treatment Management Plans: A Multi-National Qualitative Study","volume":"16","author":"Giocanti-Aur\u00e9gan","year":"2022","journal-title":"Pat Prefer Adherence"},{"key":"2026010721201362000_10.1.e001967.102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.04.010"},{"key":"2026010721201362000_10.1.e001967.103","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201810204","article-title":"Efficacy of simultaneous VEGF-A\/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization","volume":"11","author":"Foxton","year":"2019","journal-title":"EMBO Mol Med"},{"key":"2026010721201362000_10.1.e001967.104","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41433-018-0225-x","article-title":"Asian age-related macular degeneration: from basic science research perspective","volume":"33","author":"Yanagi","year":"2019","journal-title":"Eye (Lond)"},{"key":"2026010721201362000_10.1.e001967.105","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.12.013"},{"key":"2026010721201362000_10.1.e001967.106","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10384-023-00979-8","article-title":"Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial","volume":"67","author":"Shimura","year":"2023","journal-title":"Jpn J Ophthalmol"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2024-001967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:20:44Z","timestamp":1767849644000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2024-001967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,16]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjophth-2024-001967"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2024-001967","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}